SQZ Biotechnologies (OTCMKTS:SQZB – Get Free Report) will likely be posting its resultson Friday, August 14th. Analysts expect the company to post earnings of ($0.5825) per share and revenue of $4.6620 million for the quarter.
SQZ Biotechnologies Stock Performance
SQZB stock opened at $0.02 on Wednesday. The firm has a market capitalization of $707,760.00, a PE ratio of -0.04 and a beta of 0.33. SQZ Biotechnologies has a 1-year low of $0.02 and a 1-year high of $0.05. The business’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.02.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies (OTCMKTS:SQZB) is a clinical-stage biotechnology company focused on developing novel cell therapies through its proprietary microfluidic delivery technology. The company’s core “Cell Squeeze” platform temporarily disrupts cell membranes to enable direct intracellular delivery of a wide range of biomolecules, including proteins, peptides and nucleic acids, without relying on viral vectors. This approach is designed to improve manufacturing efficiency, enhance safety profiles and broaden the applicability of cell-based therapies across multiple disease areas.
The company’s pipeline spans oncology, infectious disease and regenerative medicine.
See Also
- Five stocks we like better than SQZ Biotechnologies
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
